Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Tennessee: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 150 | 43% |
| 2020 | 0 | 146 | 46% |
| 2021 | 3 | 145 | 49% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Tennessee; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 10 | 360−6%/yr | −6%/yr | 0.51.3× | 0% | 300 in 2030−3%/yr |
| Aneurysm & intracranial embolization |
CSF shunts in every state, and its device makers · Every procedure market in Tennessee · Every state · Compare with Florida
| 2024 |
| 130 |
| 57% |
| 2025 est. | ≈ 130 | – |
| 2026 est. | ≈ 130 | – |
| 2022 | 0 | 127 | 52% |
| 2023 | 3 | 144 | 55% |
| 2024 | 2 | 130 | 57% |
| 2025 from claims | – | 127 103–149 | 57% |
| 2026 forecast | – | 128 101–161 | 58% |
| 2027 forecast | – | 130 96–171 | 58% |
| 2028 forecast | – | 131 93–181 | 58% |
| 2029 forecast | – | 132 90–190 | 59% |
| 2030 forecast | – | 133 87–198 | 59% |
In 2025, 100% inpatient hospital.
| −4.6%/yr |
| 0.2 |
| 0% |
| 540 in 2030+2.2%/yr |
| North Carolina | 2 | 190−7.9%/yr | −7.9%/yr | 0.2 | 0% | 170 in 2030−1.6%/yr |
| Maryland | 3 | 162−5.9%/yr | −5.9%/yr | 0.2 | 0% | 150 in 2030−1.2%/yr |
| Virginia | 3 | 129−7.5%/yr | −7.5%/yr | 0.1 | 0% | 170 in 2030+4.6%/yr |
| Louisiana | 1 | 126−3%/yr | −3%/yr | 0.3 | 0% | 260 in 2030+13%/yr |
| Georgia | 0 | 123−9.2%/yr | −9.2%/yr | 0.1 | 0% | 180 in 2030+6.5%/yr |
| 9 |
| 328+6.6%/yr |
| +6.6%/yr |
| 0.51.0× |
| 0% |
| 490 in 2030+6.8%/yr |
| DBS & VNS | 4 | 252+1%/yr | +1%/yr | 0.31.1× | 0% | 270 in 2030+1.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 90% of company spending on these surgeons in 2025, −8 pts on 2024.
In 2025, 6 companies reported engagement with Tennessee’s surgeons worth $42K in consulting, speaking, meals and travel tied to these products, about $21K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.